Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v22-EN Version v8-EN
Language English English
Date Updated 2023-04-27 2021-03-17
Drug Identification Number 00260436 00260436
Brand name DALACIN C PHOSPHATE DALACIN C PHOSPHATE
Common or Proper name Dalacin C Phosphate Dalacin C Phosphate
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients CLINDAMYCIN CLINDAMYCIN
Strength(s) 150MG 150MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 25x2mL 25x2mL
ATC code J01FF J01FF
ATC description MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-09-30
Actual start date 2021-06-14
Estimated end date 2023-04-30 2022-04-01
Actual end date 2023-04-26
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments